NovoCure Ltd — Director's Dealing 2017

Jul 7, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Novocure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2017-07-05

Reporting Person: Danziger Asaf (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-07-05	Ordinary Shares	A	2545	$6.673	Acquired	899462	Direct
2017-07-05	Ordinary Shares	S	155088	$18.144	Disposed	744374	Direct
2017-07-06	Ordinary Shares	S	5050	$18.088	Disposed	739324	Direct

Footnotes

F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is also exempt under Rule 16b-3(c).

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 3, 2017.

F3: On July 5, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 155,088 shares in multiple trades at prices ranging from $18.00 to $18.35. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F4: On July 6, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 5,050 shares in multiple trades at prices ranging from $18.00 to $18.20. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.